German State Challenges ‘GMP Washing’ in Cannabis Imports

The compliance model that underpins Germany’s booming medical cannabis trade is now under formal regulatory scrutiny in Europe’s largest market. A health authority in the German state of Hesse has challenged whether the standard way importers bring cannabis flower into the country — grown to an agricultural standard abroad, then finished at a pharmaceutical-grade facility in Europe — actually meets the quality rules that medicines must satisfy.

In a guidance document dated June 8, 2026, the Hessian State Office for Health and Care set out how it will read the existing rules governing medical cannabis imports. Its core position is blunt: the drying of cannabis flower is a pharmaceutical manufacturing step, not a farming one, and the pharmaceutical standard must therefore apply from the moment the plant is harvested. That reading takes direct aim at what the industry calls “GMP washing.”

What ‘GMP washing’ means

Two quality regimes govern medical cannabis. Cultivation, harvesting, and initial handling fall under Good Agricultural and Collection Practice, or GACP, a lighter agricultural standard. Everything downstream — processing, testing, packaging, and the final release of each batch — falls under Good Manufacturing Practice, or GMP, the pharmaceutical standard a company must meet to sell medicines in the EU.

Most flower reaching German patients is grown to the agricultural standard abroad, then routed through an EU-GMP facility — often in Portugal, but also Canada, the Czech Republic, Malta, or Switzerland — where it picks up the GMP certification the original material never carried. Converting non-GMP flower into GMP product this way is what critics call “GMP washing.”

Why drying is the sticking point

The Hesse authority treats controlled drying as “a critical manufacturing step” with a decisive influence on product quality, which places it inside the pharmaceutical rules rather than the lighter agricultural ones. The EU’s manufacturing rules for herbal medicines do allow some cutting, and in limited cases, an initial drying step, to happen under the agricultural standard. But the authority says it knows of no process that has demonstrably shown flower can be transported over long distances, stored, imported, and processed further without any loss of quality.

The conclusion follows directly: either the flower loses its agricultural-standard status in transit, or it keeps it, but no one can prove it arrived intact. Either way, the authority argues, the pharmaceutical standard should have applied from harvest.

The guidance also tightens the screws on decontamination. Techniques used to cut microbial load — including irradiation, which is common for flower destined for inhalation — count as reprocessing under the EU rules, permitted only in exceptional cases and after a full risk assessment. Where such treatment is applied routinely across batches, the authority says it must be built into the validated standard process, not bolted on after the fact. Pharmaceutical experts have also flagged that the microbiological limit the guidance leans on was written for products taken orally, leaving open how it should apply to cannabis meant to be inhaled.

The practical bite lands in the paperwork. Every import application must now come with a diagram showing at which facility, by which supplier, and under which standard each processing step took place. If the supply chain raises doubts, the authority can demand further documentation to validate how the flower was transported and stored — and the qualified person who signs off each batch under German medicines law remains on the hook regardless of where those steps happened.

A model under strain

The timing matters because Germany’s import market has exploded. The country imported roughly 201 tonnes of medical cannabis flower in 2025, nearly triple the previous year’s total, with Canada supplying close to half and Portugal serving as the main processing gateway into the EU. With only three licensed domestic producers, Germany leans on imports to supply an estimated 900,000-plus patients — and almost all of that flower moves through exactly the agricultural-to-pharmaceutical route the Hesse guidance now questions.

The document is an information sheet rather than a binding regulation, which raises the question of whether operators must comply or could contest it. In the reading of German cannabis lawyers, there is little room to fight: the guidance reflects existing law rather than inventing a new rule, and there is no entitlement to “GMP washing.” Regulators, they note, are well within their rights to demand the documentation, validations, and risk assessments needed to prove pharmaceutical quality.

How far it could spread

Import licensing in Germany sits with individual states, and their approaches already diverge — some treat imported flower as an active ingredient that needs no EU-GMP certificate, others as a finished medicine that does. That fragmentation is exactly why a single state’s stance carries weight. Industry reports indicate Hesse is not acting alone: a second guidance has surfaced covering the Darmstadt district, echoing a position regulators in Cologne had already taken against the practice.

Because the underlying requirement flows from EU pharmaceutical law, which makes good manufacturing practice mandatory for making medicines, authorities in other member states could bring the same challenge — part of a broader pattern of tightening medical cannabis rules across the bloc.

For importers, the message is that the years-long arrangement of growing cheaply to an agricultural standard and buying pharmaceutical credibility at the European border is narrowing. Operators that already control drying and processing under pharmaceutical conditions from harvest onward are best placed; those relying on third-party finishing now have to prove, batch by batch, that quality survived the journey. Whether Hesse’s reading stays contained or becomes the European norm is the question the rest of the market will be watching.